Waage Ingunn Syversen, Vreim Ingeborg, Torp Sverre Helge
1Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Int J Surg Pathol. 2013 Dec;21(6):573-82. doi: 10.1177/1066896913492196. Epub 2013 Jul 9.
C-erbB2/HER2 serves as an important prognostic and predictive biomarker in various human tumors, especially in breast cancer, whereas its role in human intracranial tumors is more uncertain. We therefore performed a search in PubMed to get an update. This literature review comprises immunohistochemical studies on the clinical significance of c-erbB2/HER2 overexpression in gliomas, medulloblastomas, and meningiomas. In general, the findings were discrepant with regard to correlations between overexpression, tumor grade, and prognosis. Use of various antibodies may be a contributing factor to these discrepancies. Standardization of the immunohistochemical procedures is a relevant topic for discussion.
C-erbB2/HER2作为多种人类肿瘤尤其是乳腺癌中重要的预后和预测生物标志物，而其在人类颅内肿瘤中的作用则更具不确定性。因此，我们在PubMed上进行了检索以获取最新信息。这篇文献综述包括了关于c-erbB2/HER2在胶质瘤、髓母细胞瘤和脑膜瘤中过表达的临床意义的免疫组化研究。总体而言，关于过表达、肿瘤分级和预后之间的相关性，研究结果存在差异。使用各种不同的抗体可能是导致这些差异的一个因素。免疫组化程序的标准化是一个值得讨论的相关话题。
